GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone

GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.

Fist Bump
GSK has teamed up with iTeos on a TIGIT antibody • Source: Alamy

GlaxoSmithKline plc is investing heavily to build a solid presence in what could be the next big competitive field in immuno-oncology – TIGIT. The company announced on 14 June that it will pay $625m up front for rights to iTeos Therapeutics Inc.'s EOS-448, an anti-TIGIT monoclonal antibody in Phase I development for cancer.

The deal is an expensive one in an area where many big pharmas have already bolstered their pipelines. Roche...

More from Anticancer

More from Therapeutic Category